Skip to main content
padlock icon - secure page this page is secure

Open Access Projet Ra&D à l'Ecole d'Ingénieurs et d'Architectes de Fribourg Développement d'un Nouvel Agent Anti-SIDA: NU 1320

Download Article:
(PDF 165.5 kb)
The division of chemistry at the School of Engineering and Architecture of Fribourg is involved with the School of Engineering of Geneva in the development of a new drug for the treatment of AIDS. This recently discovered molecule, called NU 1320, has already shown a powerful antiviral activity. NU 1320 is a nonnucleoside inhibitor, which stops the formation of the retrotranscription complexe of the HIV-virus. The concentration of NU 1320 to inhibit 50% of viral replication is 10–6 nM: such a low concentration and the non-toxicity will prevent the occurrence of side effects for the patient. As a future potential HIV drug, the University of Applied Sciences of Western Switzerland (HES-SO) has invested in this research with the start of a project for the scale-up of this new antiviral molecule with the intention to perform in vivo tests.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: January 1, 2004

More about this publication?
  • International Journal for Chemistry and Official Membership Journal of the Swiss Chemical Society (SCS) and its Divisions

    CHIMIA, a scientific journal for chemistry in the broadest sense, is published 10 times a year and covers the interests of a wide and diverse readership. Contributions from all fields of chemistry and related areas are considered for publication in the form of Review Articles and Notes. A characteristic feature of CHIMIA are the thematic issues, each devoted to an area of great current significance.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Information for Advertisers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more